Sickle cell disease, vasculopathy, and therapeutics

Area of Science:

• Hematology
• Vascular Biology
• Genetics

Background:

• Sickle cell disease (SCD) stems from beta globin gene mutations, leading to chronic hemolysis, vaso-occlusion, and multiorgan damage.
• Pathogenesis involves HbS polymerization and endothelial dysfunction, influenced by hemolysis, nitric oxide defects, oxidative stress, and inflammation.

Purpose of the Study:

• To review evidence linking sickle cell disease vasculopathy to subsequent organ dysfunction.
• To explore the potential of targeted antivasculopathy therapies for SCD management.

Main Methods:

• Literature review of studies on SCD pathogenesis and vasculopathy.
• Analysis of organ-specific vasculopathies and their predictive value for dysfunction.
• Evaluation of therapeutic strategies targeting vascular abnormalities in SCD.

Main Results:

• SCD-related vasculopathies, including moyamoya, retinopathy, pulmonary hypertension, and renal disease, often precede overt organ dysfunction.
• These vascular changes are critical indicators of disease progression and potential therapeutic targets.

Conclusions:

• Sickle cell disease vasculopathy serves as an early warning sign for organ damage.
• Targeted antivasculopathy treatments hold promise for mitigating SCD-related morbidity and mortality.